The company said it appointed Andrew Hider as President, CEO and a Board member in August 2025, and that in connection with the appointment it separated the Chair and CEO roles, with Brent Shafer serving as Non-Executive Chair.

8-KRegulation FD DisclosureFiled Mar 19, 2026Period of report Mar 19, 2026Summary published (UTC) Oct 2, 2026

Key points

AI summary

The company said it appointed Andrew Hider as President, CEO and a Board member in August 2025, and that in connection with the appointment it separated the Chair and CEO roles, with Brent Shafer serving as Non-Executive Chair.
Baxter said Anita Zielinski, its CAO and Controller, was named interim CFO effective March 2026 following the departure of Joel Grade, and that it is searching for a permanent CFO.
Baxter said its global reported sales from continuing operations for December 31, 2025 were $11.2B and its adjusted operating margin was +20 basis points. It said it is targeting net leverage of about 3.0x by the end of 2026.
Baxter said Michael McDonnell joined the Board and the Audit Committee in February 2026. It also said William Ampofo will assume the role of Quality and Regulatory Compliance Committee Chair in May 2026, in connection with Dr. Stephen Oesterle's retirement.

Summary

AI-written

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

CEO Appointment and Separation of Chair and CEO Roles

The company said it appointed Andrew Hider as President, CEO and a Board member in August 2025, and that in connection with the appointment it separated the Chair and CEO roles, with Brent Shafer serving as Non-Executive Chair.

Source · Based on the filing body and exhibits

CFO Departure and Interim CFO Appointment

Baxter said Anita Zielinski, its CAO and Controller, was named interim CFO effective March 2026 following the departure of Joel Grade, and that it is searching for a permanent CFO.

Source · Based on the filing body and exhibits

2025 Full-Year Results and Debt Repayment Target

Baxter said its global reported sales from continuing operations for December 31, 2025 were $11.2B and its adjusted operating margin was +20 basis points. It said it is targeting net leverage of about 3.0x by the end of 2026.

Source · Based on the filing body and exhibits

Board Refreshment and Committee Chair Changes

Baxter said Michael McDonnell joined the Board and the Audit Committee in February 2026. It also said William Ampofo will assume the role of Quality and Regulatory Compliance Committee Chair in May 2026, in connection with Dr. Stephen Oesterle's retirement.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.